Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
23.83 USD | -0.31% | -0.67% | -1.89% |
31/05 | Sector Update: Financial Stocks Rise Late Afternoon | MT |
31/05 | Sector Update: Financial | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 9.04 and 7.65 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- One of the major weak points of the company is its financial situation.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.89% | 49.97B | - | ||
+7.83% | 76.45B | B- | ||
+6.48% | 50.23B | B | ||
+21.28% | 46.96B | B+ | ||
+10.63% | 42.14B | B+ | ||
+21.64% | 39.33B | B | ||
+18.25% | 34.05B | B | ||
-1.92% | 28.68B | B | ||
-8.25% | 27.44B | B- | ||
+28.31% | 26.37B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MET Stock
- MET.PRE Stock
- Ratings MetLife, Inc.